tirzepatide surmount-1 weight loss percent nejm 2022 SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions surmount-1 tirzepatide weight loss percent
Description
This medication, initially developed for managing Obesity and type 2 diabetes, has proven to be highly effective in promoting significant weight loss
The trial had been scheduled to begin in June in the U.S
Learn about your presription drug coverage &
Anlisis clnico detallado sobre la semaglutida 2.4 mg
This would establish Wegovy, and possibly other potent anti-obesity therapies, as a backbone of CV risk management, with far-reaching implications beyond a change in clinical practice
